文献速递浆细胞疾病

泊马度胺-地塞米松治疗难治性多发性骨髓瘤:多队列II期临床试验的长期随访

Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial.
PubMed 文献 · Leukemia · 2017-09-01

该多队列II期试验在345例难治性多发性骨髓瘤患者中测试不同剂量和方案的泊马度胺-地塞米松(Pom/dex),中位既往治疗线数为3,确认缓解率35%(范围23-65%),既往治疗线数较少的队列缓解率更高;2 mg泊马度胺剂量下缓解率更高、不良事件更少。

要点

  • 345例难治性多发性骨髓瘤患者入组六个队列,中位既往治疗线数为3。
  • 所有队列确认缓解率35%(范围23-65%),既往治疗线数较少者缓解率更高。
  • 2 mg泊马度胺剂量下治疗和缓解持续时间更长、缓解率更高且不良事件更少。

核心结论

  • 这是Pom/dex治疗难治性多发性骨髓瘤随诊时间最长的数据,有助于指导该方案在真实世界中的应用。

研究设计与样本

  • 多队列II期临床试验,共纳入345例难治性多发性骨髓瘤患者,按既往治疗线数和类型、泊马度胺剂量及给药方案分为六个队列。

主要发现

  • 所有队列确认缓解率为35%(范围23-65%),既往治疗线数较少的队列缓解率更高。
  • 确认缓解的中位时间≤2个月,任一队列中最长的无进展生存期和总生存期分别为13.1个月和47.9个月。
  • 最常见血液学不良事件为骨髓抑制,最常见非血液学不良事件为疲乏。
  • 2 mg泊马度胺剂量下治疗和缓解持续时间更长、缓解率更高且不良事件更少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite therapeutic advances, multiple myeloma remains incurable, with limited options for patients with refractory disease. We conducted a large, multi-cohort clinical trial testing various doses and treatment schedules of pomalidomide and dexamethasone (Pom/dex) in patients with refractory multiple myeloma. Overall, 345 patients were enrolled to six cohorts based on number and type of prior lines of therapy, pomalidomide dose and schedule. Median prior lines of therapy were three with near universal prior exposure to proteasome inhibitors and/or immunomodulatory drugs. A confirmed response rate of 35% was noted for all cohorts (range 23-65%) with higher responses in cohorts with fewer prior lines of therapy. Median time to confirmed response was ⩽2 months and the longest progression-free survival and overall survival seen in any cohort were 13.1 and 47.9 months, respectively. Observed adverse reactions were as expected, with myelosuppression and fatigue being the most common hematologic and non-hematologic adverse events (AEs), respectively. Longer durations of treatment and response, higher response rates and fewer AEs were noted with the 2 mg pomalidomide dose. This is the longest follow-up data for Pom/dex in refractory multiple myeloma and will help shape the real-world utilization of this regimen.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ailawadhi S, Mikhael JR, LaPlant BR, et al. Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. Leukemia. 2017. PMID: 28860655. doi:10.1038/leu.2017.258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。